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Abstract
Introduction: The A673T mutation in the amyloid precursor protein (APP) protects against Alzheimer’s disease by
reducing β-amyloid protein (Aβ) production. This mutation reduced the release of the soluble APP fragment (sAPPβ),
which is processed by β-secretase, suggesting a concomitant decrease in the β-carboxyl fragment of APP (C99), which
is a direct substrate of γ-secretase for Aβ production. However, it remains controversial whether the level of C99 is
significantly reduced in cells expressing APP that carry A673T as the cause of reduced Aβ production. Here, we
investigated the effect of the A673T mutation in C99 on γ-cleavage in cells.
Results: We found that the level of C99 in cells expressing APP A673T was indistinctive of that observed in cells
expressing wild-type APP, although the release of sAPPβ was significantly reduced in the APP A673T cells. In addition,
our reconstituted β-secretase assay demonstrated no significant difference in β-cleavage on an APP fragment carrying
the A673T mutation compared with the wild-type fragment. Importantly, cells expressing C99 containing the A673T
mutation (C99 A2T; in accordance with the Aβ numbering) produced roughly half the level of Aβ compared with the
wild-type C99, suggesting that the C99 A2T is an insufficient substrate of γ-secretase in cells. A cell-free γ-secretase
assay revealed that Aβ production from the microsomal fraction of cells expressing C99 A2T was diminished. A
sucrose gradient centrifugation analysis indicated that the levels of the C99 A2T that was codistributed with γ-secretase
components in the raft fractions were reduced significantly.
Conclusions: Our data indicate that the A673T mutation in APP alters the release of sAPPβ, but not the C99 level, and
that the C99 A2T is an inefficient substrate for γ-secretase in cell-based assay.
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Introduction
Senile plaques are one of neuropathological hallmarks of
Alzheimer’s disease (AD) and composed of β-amyloid pro-
tein (Aβ). Aβ is a small protein consisting of 38–43 resi-
dues that is produced from the amyloid precursor protein
(APP) via sequential cleavage by β- and γ-secretases [1–5].
Longer forms of Aβ, such as Aβ42 and Aβ43, are prone to
aggregation and are initially deposited in the brain [6].
Familial AD (FAD) mutations in APP, presenilin 1, and pre-
senilin 2 increase the ratio of Aβ42/Aβ40. We found previ-
ously that FAD mutations preferentially produced a longer
form of the APP intracellular domain (AICD49–99), rather
than AICD50–99, and that the expression of Aβ48, as a
counterpart of AICD49–99, resulted in an increase in
Aβ42/Aβ40 ratio, as found for FAD mutations [7, 8].
Genetic analyses in AD provide not only insights into
the molecular mechanisms underlying the pathogenesis
of AD, but also a perspective regarding the prevention
and cure of the disease. Recently, the A673T mutation
in APP was reported as a novel protective mutation
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against AD that acts by reducing Aβ production [9].
Although this mutation seems to be restricted to Iceland
and Nordic countries, this finding, together with FAD
mutations, strongly supports the amyloid hypothesis
[10–17]. The A673T mutation causes a substantial
decrease in the level of the soluble APP fragment proc-
essed by β-secretase (sAPPβ) [9, 18]. It is reported that
the level of the β-carboxyl fragment of APP (C99, also
known as βCTF and CTFβ), which is a direct substrate
of γ-secretase for Aβ production, in cells expressing
APP A673T was one fourth of that detected in cells
expressing APP wild-type (WT), which suggests the con-
comitant decrease of C99 as a counterpart of sAPPβ
[18]. Conversely, Benilova and colleagues reported that
cells expressing APP A673T exhibited no significant
difference in the levels of C99 compared with cells
expressing WT APP, in spite of a nearly two hundredth
reduction in sAPPβ levels [19]. Thus, it is unclear
whether a decrease in sAPPβ leads to a concomitant de-
crease in C99 as a cause of reduced Aβ production in
cells expressing APP A673T.
Recently, we found that γ-secretase preferentially cleaved
substrates with a short ectodomain, which supports the
idea that γ-secretase recognizes the amino terminus of the
substrate [20, 21]. The A673T mutation (i.e., A2T; in
accordance with the Aβ numbering) lies within the amino
terminus of the C99 substrate. It remains unknown
whether the A2T substitution in C99 affects γ-secretase-
dependent cleavage in cells. In this study, we examined the




Cell lysates and conditioned media were subjected to
western blotting using the following antibodies: 6E10 (total
Aβ; Covance), 82E1 (total Aβ; IBL), E50 (total Aβ), BA27
(Aβ40), BC05 (Aβ42), and anti-GFP (Santa Cruz) [22, 23].
Constructs
The C99-FLAG tag-coding region was fused to the APP
signal peptide. Additional Asp and Ala residues were
inserted between the APP signal peptide and C99-FLAG,
which allowed precise cleavage at the β-cleavage site, gen-
erating C99 and Aβ species that start from Asp-1 [8, 24].
This C99-FLAG coding region or full-length APP region
was inserted prior to the internal ribosome entry site
(IRES) of pMXIG. This construct allows cells to express
GFP as an internal standard. For pulse-chase analysis, the
full-length APP-FLAG tag-coding region was inserted into
pcDNA4/TO (Invitrogen) and transfected in T-Rex CHO
cells (Invitrogen).
Pulse-chase analysis of APP processing
T-Rex CHO cells were cultured in 12-well plates and
transfected with pcDNA4/TO carrying full-length APP
(WT or A673T) [25]. Twenty-four hours later, cells were
treated with tetracycline at a concentration of 1 μg/mL
for 4 h, to express APP. Cells were washed twice in
tetracycline-free medium and incubated in the medium
for 24 h. Cells and media were collected every 4 h and
subjected to western blotting, to visualize and quantify
the levels of APP, sAPPβ, sAPPα, C99, C83, and Aβ.
Secretase assays
A γ-secretase assay and coimmunoprecipitation analyses
were performed as described previously [21, 26]. Briefly,
the C99-FLAG substrate was expressed in sf9 cells and
purified using anti-FLAG M2 agarose beads. The C99-
FLAG substrate was incubated with a γ-secretase fraction
for 4 h and subjected to western blotting. For coimmuno-
precipitation of C99 with γ-secretase components, the
C99-FLAG substrate was immobilized on anti-FLAG M2
magnetic beads and incubated with a γ-secretase fraction.
For β-secretase assay, the human APP fragment 633–685
(numbering from APP751) fused with N-terminal Myc and
C-terminal FLAG tags (referred to as APP633–685-FLAG)
was expressed in Escherichia coli BL21 cells and affinity
purified using ANTI-FLAG M2 beads [21]. The purified
APP633–685-FLAG (500 nM) was incubated with β-
secretase (Sigma) for 4 h, according to the manufac-
turer’s instructions. β-Cleaved C-terminal fragments
(Aβ33-FLAG) from APP633–685-FLAG were visualized
and quantified using the E50 antibody.
Cell-free γ-secretase assay
Cells were cultured in Dulbecco’s modified Eagle’s medium
(Sigma) supplemented with 10 % FBS (Invitrogen) and
penicillin/streptomycin (Invitrogen). Harvested cells were
homogenized in Buffer A (20 mM PIPES, pH 7.0, 140 mM
KCl, 0.25 M sucrose, and 5 mM EGTA) with a glass/Teflon
homogenizer. Postnuclear supernatants were subjected to
ultracentrifugation at 100,000 g for 1 h. The pellets were
resuspended in Buffer A at a protein density of 2.5 mg/mL
and defined as microsomal fractions [27]. Microsomal frac-
tions from C99 WT and C99 A2T cells were incubated at
37 °C and lipids were extracted with chloroform/methanol
before western blotting.
Isolation of CHAPSO-insoluble fractions
The CHO homogenate was adjusted to 40 % sucrose and
centrifuged on a discontinuous sucrose gradient for 20 h
at 4 °C using an SW 41 Ti rotor (Beckman) [28, 29]. After
centrifugation, the homogenate was fractionated into 12
fractions and subjected to western blotting using the
following antibodies: N1660 (Nicastrin; 1/3000 in TBS
containing 0.1 % Tween; Sigma), anti-Aph-1a C-term
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antibody (Aph-1; 1/1000 in TOYOBO Can Get Signal;
Covance), anti-PS1–CTF antiserum (Presenilin 1 CTF; 1/
3000 in TBS containing 0.1 % Tween; gifts from Drs. T.
Iwatsubo and T. Tomita, The University of Tokyo),
anti-Pen-2 antibody (Pen-2; 1/3000 in TBS containing
0.1 % Tween; a gift from Dr. A. Takashima, National
Center for Geriatrics and Gerontology), anti-caveolin
antibody (caveolin-1; 1/1000 in TBS containing 0.1 %
Tween; Santa Cruz), and anti-flotillin antibody (flotillin-
1; 1/1000 in TBS containing 0.1 % Tween; BD).
Results
Effect of the A673T mutation on C99 levels in cells
The A673T mutation in APP reduced the release of
sAPPβ [9]. We also observed that the secretion of sAPPβ
into the medium was diminished in CHO cells expressing
APP A673T (APP A673T cells) (Fig. 1); however, the levels
of C99 carrying A2T (C99 A2T) in APP A673T cells were
not affected, which was in agreement with the study re-
ported by Benilova and colleagues (Fig. 1b and c) [19]. To
assess the rates of sAPPβ, C99, and Aβ generation from
APP A673T, we performed a pulse-chase analysis of APP
processing using the Tet-ON expression system (Fig. 2a).
Although the generation rates of sAPPβ and Aβ in APP
A673T cells were attenuated, the generation rate of C99 in
these cells was comparable to that observed in APP WT
cells (Fig. 2b and c). Our observation was discrepant with
a previous report [18]. To explain this disagreement, we
focused on the immunoreactivity of 82E1, the antibody
used in the ELISA system in the previous study. 82E1 was
developed for amino-terminus-specific Aβ detection [22].
Our western blot analyses indicated that 82E1 failed to
detect C99 A2T and Aβ A2T (Additional file 1: Figure S1).
To confirm further the immunoreactivity of 82E1 on C99
A2T in A673T cells, we performed immunoprecipitation
of C99 A2T using 6E10 and 82E1. 6E10 captured C99,
regardless of the substitution, whereas 82E1 failed to bind
to C99 A2T (Additional file 1: Figure S2A). We also
immunoprecipitated C99 A2T in the APP A673T cells with
anti-FLAG M2 antibody recognizing carboxyl terminal of
APP-FLAG and detected C99 A2T in APP A673T cells as
well as C99 WT in APP WTcells with anti-FLAG M2, but
not 82E1 (Additional file 1: Figure S2B). Our data demon-
strated that the level of C99 in APP A673T cells was com-
parable to that detected in APP WT cells, despite a
significant reduction in sAPPβ, suggesting that the level of
C99 in APP A673T cells is insufficient to explain the
reduced level of Aβ secreted by these cells.
Effect of the A673T mutation on the β-cleavage of the
APP fragment
The reduction in sAPPβ level observed in APP A673T
cells suggests a reduced β-cleavage in APP A673T. How-
ever, we detected no significant reduction in C99 levels
in APP A673T cells. This raises the possibility that the
A673T mutation has no significant impact on the β-
cleavage of APP. Although pioneer studies have demon-
strated reduced β-cleavage of APP A673T, we revisited
this issue [9, 18]. We previously established a reconsti-
tuted β-secretase assay using the APP 633–685 substrate
[21]. In this study, we examined the effect of the A673T
mutation on the β-cleavage of the substrate carrying the
mutation in our assay system. As shown in Fig. 3, APP
633–685-FLAG carrying A673T exhibited a level of
Aβ33-FLAG production that was equivalent to that of
the WT in our assay. This indicates that the A673T mu-
tation does not affect the β-cleavage of APP.
Effect of the A2T substitution on C99 regarding Aβ
production in cells
To uncover the molecular mechanism underlying the in-
volvement of the A673T mutation in reduced Aβ pro-
duction, we tested whether the A2T substitution in C99
directly suppressed Aβ production in cells (Fig. 1a). Im-
portantly, CHO cells expressing C99 A2T (C99 A2T
cells) released approximately half the levels of Aβ40 and
Aβ42 into the medium in the case of the WT C99 (C99
WT cells), whereas p3 40 levels in the C99 A2T medium
were not affected at all (Fig. 4a). The alteration of Aβ se-
cretion by the expression of C99 A2T was observed even
in other cell lines (Additional file 1: Figure S3). In
addition, we found a significant reduction in intracellular
Aβ in C99 A2T cells (Fig. 4b and c). These data demon-
strate that the A2T substitution in C99 suppresses Aβ
production in cells.
No effect of the A2T substitution in C99 on its γ-cleavage
in a membrane-soluble state
The A2T substitution lies within the amino terminus of
C99, which is recognized by γ-secretase [20, 21]. One may
expect that γ-secretase would fail to recognize C99 A2T
because of suppressed Aβ production. To test this possibil-
ity, we performed a CHAPSO-solubilized γ-secretase assay
using the C99 A2T substrate, which allows free collision
between the enzyme and substrate in the solution. Despite
intensive analyses, we detected no significant reduction in
Aβ production from recombinant C99 A2T in the solution
(Fig. 5a). Moreover, a coimmunoprecipitation analysis re-
vealed that the interaction between C99 A2T and γ-
secretase components was not affected in the presence or
absence of DAPT (Fig. 5b and c) [21].
Effect of the A2T substitution on Aβ production in
microsomal fractions
Data regarding Aβ production in the CHAPSO-solubilized
γ-secretase assay contradicted the results of the cell-based
assay in terms of C99 cleavage by γ-secretase. One possible
explanation for this discrepancy is the altered distribution
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of C99 A2T at the membrane. C99 A2T may be recognized
by γ-secretase inefficiently in certain membrane compart-
ments, resulting in the inhibitory effect of the A2T substi-
tution on Aβ production in cells. To test this possibility,
we performed a cell-free assay using the microsomal frac-
tion of C99 A2T cells. We observed that C99 A2T yielded
a significant decrease in Aβ production in the cell-free
assay, although the levels of C99 A2T and C99 WT were
almost the same (Fig. 6). These findings imply that the
A2T substitution alters the subcellular distribution of C99,
which leads to interference with the interaction between γ-
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Fig. 1 The A673T substitution in APP decreased sAPPβ secretion, but not C99. Constructs used in this study. The APP695- or C99-coding fragment
was inserted prior to IRES-GFP in pMXIG (a). APP A673T cells released one third of the levels of sAPPβ compared with those of wild-type APP. However,
C99 levels in APP A673T cells were statistically indistinguishable from those of APP WT cells (b). Levels of sAPPβ and C99 were normalized for amount of
APP (c). C99 level in APP A673T cells was almost identical to that in wild-type APP cells, as well as from internal standard GFP expression levels (d). Data
represent means ± SD of three independent experiments. NS, not significant; * P< 0.05 (unpaired t-test)
Kokawa et al. Acta Neuropathologica Communications  (2015) 3:66 Page 4 of 12
atetracycline




0 4 8 12 16 20 24 28 0 4 8 12 16 20 24 28 h


















































































































Time (h) Time (h)
























Time (h) Time (h)
104 104C83 sAPP
Fig. 2 (See legend on next page.)
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Altered distribution of C99 A2T in lipid rafts
Active γ-secretase accumulates in detergent-insoluble
fractions (lipid raft) of membranes prepared by sucrose
gradient centrifugation [30–32]. C99 also distributes to
these fractions, in part. To investigate whether C99 A2T
exhibits an altered distribution in lipid rafts, C99 A2T
cells were treated with 1 % CHAPSO and subjected to
sucrose gradient centrifugation as described previously
[28, 29]. Importantly, the levels of the C99 A2T that was
codistributed with γ-secretase components in the raft
fractions were reduced significantly, although we ob-
served no prominent difference between C99 WT and
C99 A2T in membrane, cytosolic and nuclear fractions
(Fig. 7; Additional file 1: Figure S4-S5). Our data suggest
that the altered subcellular distribution of C99 can result
in a moderate interaction between C99 and γ-secretase
in cells, and in a reduction in Aβ production.
Discussion
The A673T mutation in APP has been recognized as a
protective variant of late-onset of AD and has been related
to longevity in an Icelandic population [9]. Although this
variant is extremely rare in non-Nordic countries, it is im-
portant to explore the mechanism of reduced Aβ produc-
tion [14]. Biochemical and cell-based assays demonstrated
reductions in the β-cleavage on an APP A673T fragment
and in sAPPβ release from APP A673T cells, which sug-
gests that reduced C99 production results in a reduction of
Aβ production [9, 18]. In fact, β-cleavage has been a prom-
ising drug target for anti-AD therapeutics, to reduce C99
and Aβ [2, 33]. However, Benilova and colleagues observed
no significant difference in the levels of C99 between APP
WT and A673T cells, despite a substantial reduction in
sAPPβ level [19]. This discrepancy prompted us to revisit
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Fig. 3 β-Secretase-dependent cleavage of the APP A673T fragment. An APP751 fragment (633–685) fused with FLAG tag (APP633–686-FLAG) was
incubated with β-secretase. The E50 antibody was used to visualize the equal amounts of Aβ33-FLAG that were produced by β-secretase from the WT of
the APP633–686-FLAG substrate and its A673T mutant substrate. The reaction solution of the WT substrate was loaded onto a gel, as indicated by standard
curve. Data are expressed as means ± SD of three independent experiments. An unpaired t-test detected no significant differences between substrates
(See figure on previous page.)
Fig. 2 Pulse chase analysis of APP processing. Schematic diagram of pulse chase analysis of APP processing (a). CHO cells were transfected with
APP WT or APP A673T construct and treated with 1 μg/ml tetracycline for 4 h. After replacing media, cells and media were collected at the time indicated.
Detection of APP, sAPPβ, C99, Aβ, C83 and sAPPα by Western Blotting (b). C99 was barely detected by using anti-FLAG antibody, although robust C83
bands were visualized. Quantitative analyses of APP, sAPPβ, C99, Aβ, C83 and sAPPα (c). Levels of sAPPβ and Aβ were reduced in APP A673T
cells compared with those in APP WT cells, while levels of APP and C99 were almost similar to those of APP WT cells. It is interesting to note
that generation rate of C83 is distinct from those of APP and C99. Data represent means ± SD of three independent experiments. Open circle,
WT; closed circle, A673T. *P < 0.05; **P < 0.01 (unpaired t-test)
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C99 in APP A673T cells was comparable to that detected
in APP WT cells, despite a significant reduction in sAPPβ.
Currently, we do not have clear interpretations of the dis-
crepancy between the amount of sAPPβ and C99 levels in
APP A673T cells. However, it is interesting to note that the
generation rate of C83 was distinct from that of C99, al-
though the generation curves of sAPPα and sAPPβ had
some resemblance to each other (see Fig. 2b and c). This
suggests that the levels of those soluble APP fragments do
not reflect the levels of their stubs in cells precisely.
Our reconstituted β-secretase assay demonstrated that
the APP633–685 fragment carrying A673T was cleaved
by β-secretase, as was the WT APP638–685 fragment.
This result was consistent with our quantitative analyses
a
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Fig. 4 Conditioned media of C99 WT and C99 A2T cells were subjected to Western blotting to visualize and quantify the Aβ and p3 species. C99
A2T cells exhibited reduced levels of Aβ40 and Aβ42, but not of p3 40 (a). Lysates of transfectants were subjected to Western blotting, to visualize and
quantify GFP, C99, and intracellular Aβ (b). The lysate of C99 WT cells was loaded into a gel, as indicated by standard curve. The levels of GFP and C99
in cells expressing C99 WT and C99 A2T were indistinctive, whereas intracellular Aβ levels were significantly reduced in C99 A2T cells. Data represent
means ± SD of three independent experiments (c). NS, not significant. * P < 0.05 (unpaired t-test)
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of C99 levels on A673T cells; however, it was inconsist-
ent with the result of the cell-based assay of sAPPβ as
reported previously [9, 18]. One possible interpretation
for the inconsistent results between the reconstituted β-
secretase assay and the cell-based assay is that APP
A673T is preferentially processed by an unknown en-
zyme, leading to a reduced level of sAPPβ from APP
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Fig. 5 CHAPSO-solubilized γ-secretase assay. Recombinant C99-FLAG substrates were incubated with solubilized γ-secretase and subjected to Western
Blotting to visualize and quantify levels of Aβ production (a). Aβ production from C99 A2T was indistinctive to that from C99 WT. Data represent means ±
SD of three independent experiments. NS, not significant (unpaired t-test). Substrates were immobilized on anti-FLAG magnetic beads and incubated with
CHAPSO-solubilized γ-secretase (b). After sufficient wash, the beads were subjected to Western Blotting. γ-Secretase interacted with C99 A2T as well as
C99 WT. -, DMSO vehicle control; D, 1 μM DAPT. Quantitative analyses of interacted γ-secretase components (c). Data represent means ± SD of three
independent experiments in the absence of 1 μM DAPT. NS, not significant (ANOVA, Scheffe’s post hoc test compared with WT DMSO)
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η-secretase as a novel APP-processing enzyme that pro-
duces a high-molecular-weight carboxyl terminal fragment
of APP (CTFη), which can be processed into C83 and C99
by α- and β-secretases, respectively [34]. One can safely
say that η-secretase cleaves APP A673T preferentially. If
so, APP A673T cells produce a lesser amount of sAPPβ,
but an equal level of C99, compared with APP WT cells.
Alternatively, η-secretase may preferentially cleave sAPPβ
produced from APP A673T cells.
We have shown that C99 A2T cells also release a lower
amount of Aβ compared with C99 WT cells. This is direct
evidence that the A2T substitution on C99 alters Aβ pro-
duction. This was also observed for the other cell lines.
Our western blotting assay using 6E10 and E50 revealed
that Aβ A2T and C99 A2T were transferred onto nitrocel-
lulose, as were Aβ WT and C99 WT. Our data demon-
strated that 82E1 failed to recognize Aβ A2T and C99 A2T
on western blot and to capture the C99 A2T substrate on
immunoprecipitation. This indicates that our evaluation by
western blotting is reliable and that C99 A2T is an ineffi-
cient substrate for Aβ production in cells. Importantly, the
amount of the p3 peptide in the media of C99 WT and
C99 A2T cells was indistinctive, which suggests that the
A2T substitution affects the γ-cleavage of C99, but not that
of C83. We also found that the A2T substitution in C99
caused no accumulation of intracellular Aβ; rather, it re-
duced the level of intracellular Aβ. Our data demonstrated
that reduced Aβ levels in the medium of C99 A2T cells
were caused by impaired γ-cleavage of C99 A2T in cells.
We expected that C99 A2T would be an inefficient
substrate for γ-secretase even in the CHAPSO-solubilized
γ-secretase assay. However, we observed no significant re-
duction in Aβ production from the recombinant C99 A2T
substrate, and an interaction with γ-secretase components
in the CHAPSO-solubilized state. This implies that mem-
brane solubilization disrupts the intact distribution of C99
A2T, which allows free collision between the enzyme and
the substrate in the solution. To mimic the cell-based
15
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Fig. 6 The microsomal fraction of C99 A2T was incubated and subjected to Western Blotting analysis (a). Aβ production from the microsomal fraction
of C99 A2T cells was significantly reduced compared with that detected in C99 WT cells. Aβ production was determined by subtracting the amount of
Aβ at 0 min from that at 20 min. Data represent means ± SD of four independent experiments (b). NS, not significant. **P < 0.005 (unpaired t-test)
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assay in a biochemical analysis, we chose a cell-free assay
that used the microsomal fraction of cells. This approach
provides an assessment of Aβ production in intact mem-
branes. As expected, the cell-free assay reproduced the
altered Aβ production in a membrane fraction of C99
A2T cells. This suggests that the subcellular distribution
of C99 A2T is altered, and that this redistribution reduces
the interaction between C99 A2T and γ-secretase.
Conclusion
This report indicates that the C99 level in APP A673T
cells is comparable to that in APP WT cells despite a
significant reduction in released sAPPβ level, suggest-
ing vulnerable correlation between levels of sAPPβ and
C99 in cells. Our data demonstrate that the A673T mu-
tation in C99 impairs γ-cleavage the in cell-based assay.
Assessment of observed results in vivo may be crucial
to elucidate the protective mechanism of A673T muta-
tion against AD.
Availability of supporting data
The data set supporting the results of this article are in-

































































Fig. 7 C99 A2T cells were treated with CHAPSO and fractionated using sucrose gradient centrifugation (a). The presenilin 1 carboxyl terminal fragment
(PS1CTF) was enriched in raft fractions (#4 and #5). C99 was also distributed in these fractions, in part. However, C99 A2T distribution was significantly
shifted into denser fractions (#5 and #6) compared with C99 WT (#4, #5, and #6) (b). Data represent means ± SD of three independent experiments. NS,
not significant. *P < 0.05 (unpaired t-test)
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Additional file
Additional file 1: Figure S1. Immunoreactivity of anti-Aβ antibodies.
Recognition sites of anti-Aβ antibodies in the human C99/Aβ sequence
(A). A recombinant C99-FLAG containing the A2T substitution was sub-
jected to Western blotting using anti-Aβ antibodies (B). Aβ40 containing
the A2T substitution was subjected to Western blotting using anti-Aβ
antibodies (C). 82E1 failed to recognize C99-FLAG and Aβ40 containing
the A2T substitution. Figure S2. Immunoprecipitation of C99 A2T in APP
A673T cells. CHO cells expressing APP A673T were solubilized in 1% NP40
and subjected to immunoprecipitation with 6E10 or 82E1 and to Western
blotting, to visualize C99 (upper panel) (A). Immunoprecipitation with
6E10 proved that the level of C99 (C99 A2T) in APP A673T cells was indis-
tinctive of that observed in APP WT cells; however, 82E1 failed to capture
C99 A2T (upper and lower panels). These data indicate that the amount
of C99 in APP A673T cells was comparable to that detected in APP WT
cells. Arrowheads, IgG; * degradation products of APP.CHO cells express-
ing APP A673T were solubilized in 1% NP40 and subjected to immuno-
precipitation with anti-FLAG M2 antibody and to Western blotting (B).
Anti-FLAG M2 antibody visualized equal levels of C99 in APP WT and
A673T cells (left panel). The blot was reprobed with 82E1 after stripping
anti-FLAG M2 (right panel). 82E1 failed to visualize C99 from APP A673T
cells, although remnant bands were detected on the blot. These data in-
dicate that the amount of C99 in APP A673T cells was comparable to that
detected in APP WT cells. Arrowheads, IgG. Figure S3. Cells expressing
APP A673T and C99 A2T exhibited decreased extracellular Aβ production.
HEK293, Neuro 2a, and CHO cells were transfected with the APP A673T
or C99 A2T construct. Conditioned media were subjected to Western
blotting, to visualize and quantify extracellular Aβ, as in Fig. 2A. HEK,
HEK293; N2a, Neuro 2a. Data represent means ± SD of three independent
experiments. * P < 0.05; ** P < 0.005 (unpaired t-test). Figure S4. No ef-
fect of the C99 A2T substitution on the subcellular distribution of γ-
secretase components. γ-Secretase components were enriched in lipid
raft fractions, as well as caveolin and flotilin raft markers (#4 - #6) (A). The
C99 substrate also localized in the fractions, in part; however, C99 A2T
was distributed in denser fractions (#5 and #6) of raft fractions compared
with C99 WT (#4, #5, and #6) (see Fig. 1B and C). mNCT, mature nicastrin.
Quantitative analysis of the distribution of g-secretase components and
C99 substrates (B). C99 A2T was distributed in denser fractions (#5 and
#6) compared with C99 WT (#4, #5, and #6) (see Fig. 1B and C). This indi-
cated that the level of C99 A2T that was colocalized with g-secretase was
decreased. Data represent means ± SD of three independent experi-
ments. No significant difference was observed between C99 WT and C99
A2T (unpaired t-test). Individual C99 blots of each experiment (C). Levels
of C99 A2T in fraction 4 were lower than those in fraction 6. However
levels of C99 WT in fraction 4 were equivalent or higher than those in
fraction 6. Figure S5. C99 in membrane, cytosolic and nuclear fractions.
C99 cells are homogenized PEPES buffer containing 250 mM sucrose.
Postnuclear fraction was subjected to ultracentrifugation at 100,000 g for
1 h. The pellet was resuspended in the original volume of the PIPES buf-
fer and referred to as membrane fraction. Each fraction was subjected to
western blotting to visualize C99 (A). Band intensities of C99, band A and
band B in membrane (Mem), cytosolic (Cyto) and nuclear (Nuc) fractions
were quantified (B). No prominent difference was observed between C99
WT and C99 A2T. (PDF 935 kb)
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